MX22522A - Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo. - Google Patents

Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo.

Info

Publication number
MX22522A
MX22522A MX2252290A MX2252290A MX22522A MX 22522 A MX22522 A MX 22522A MX 2252290 A MX2252290 A MX 2252290A MX 2252290 A MX2252290 A MX 2252290A MX 22522 A MX22522 A MX 22522A
Authority
MX
Mexico
Prior art keywords
elaboration
interferon
procedure
same
composition containing
Prior art date
Application number
MX2252290A
Other languages
English (en)
Inventor
Alberto Ferro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX22522A publication Critical patent/MX22522A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2252290A 1989-09-28 1990-09-24 Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo. MX22522A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
MX22522A true MX22522A (es) 1993-10-01

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2252290A MX22522A (es) 1989-09-28 1990-09-24 Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo.

Country Status (26)

Country Link
EP (1) EP0420049B1 (es)
JP (1) JPH03130232A (es)
KR (1) KR910005886A (es)
CN (1) CN1050503A (es)
AR (1) AR244551A1 (es)
AT (1) ATE92334T1 (es)
AU (1) AU636653B2 (es)
CA (1) CA2024046A1 (es)
CZ (1) CZ277712B6 (es)
DD (1) DD298054A5 (es)
DE (1) DE59002183D1 (es)
FI (1) FI904756A7 (es)
HU (1) HU205555B (es)
IE (1) IE903479A1 (es)
IL (1) IL95769A0 (es)
IS (1) IS3631A7 (es)
MC (1) MC2149A1 (es)
MX (1) MX22522A (es)
MY (1) MY106615A (es)
NO (1) NO904218L (es)
NZ (1) NZ235153A (es)
PH (1) PH27531A (es)
PT (1) PT95454A (es)
RU (1) RU2008017C1 (es)
YU (1) YU184090A (es)
ZA (1) ZA907579B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
WO1997041885A1 (en) * 1996-05-09 1997-11-13 Feronpatent Limited Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
SK285284B6 (sk) * 1998-03-26 2006-10-05 Schering Corporation Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
DE102004048379A1 (de) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Federelement aus gesputterter Formgedächtnis-Legierung
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
NO861139L (no) * 1985-03-25 1986-09-26 Schering Corp Stabilt gamma-interferonpreparat.
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
IL95769A0 (en) 1991-06-30
EP0420049A1 (de) 1991-04-03
CZ277712B6 (en) 1993-03-17
FI904756A0 (fi) 1990-09-27
CN1050503A (zh) 1991-04-10
EP0420049B1 (de) 1993-08-04
DE59002183D1 (de) 1993-09-09
NZ235153A (en) 1993-03-26
JPH03130232A (ja) 1991-06-04
NO904218D0 (no) 1990-09-27
ZA907579B (en) 1991-06-26
KR910005886A (ko) 1991-04-27
YU184090A (sh) 1992-09-07
MC2149A1 (fr) 1992-03-10
RU2008017C1 (ru) 1994-02-28
CS432890A3 (en) 1992-12-16
AR244551A1 (es) 1993-11-30
HUT56284A (en) 1991-08-28
DD298054A5 (de) 1992-02-06
HU205555B (en) 1992-05-28
AU636653B2 (en) 1993-05-06
FI904756A7 (fi) 1991-03-29
MY106615A (en) 1995-06-30
IS3631A7 (is) 1991-03-29
HU906021D0 (en) 1991-03-28
NO904218L (no) 1991-04-02
AU6309890A (en) 1991-04-11
IE903479A1 (en) 1991-04-10
CA2024046A1 (en) 1991-03-29
PT95454A (pt) 1991-05-22
PH27531A (en) 1993-08-18
ATE92334T1 (de) 1993-08-15

Similar Documents

Publication Publication Date Title
MX22877A (es) Procedimiento para la preparacion de pirimidas, producto obtenido y composicion farmaceutica que lo incluye
MX9203027A (es) Derivados heterociclicos de acilaminotiazoles y composicines farmaceuticas que los contienen.
MX14663A (es) Procedimiento para la preparacion de derivados de quinazolina, producto obtenido y composicion fungicida y acaricida que lo incluye.
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
MX9202748A (es) Compuesto de arileter, proceso para su obtencion y composicion farmaceutica que los contiene.
PT98259A (pt) Processo para a preparacao de derivados de benzenacetamida que inibem hiv e de produtos intermediarios
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
AR243741A1 (es) Un procedimiento para el escabechado o adobo de un producto carnico.
IT8983386A0 (it) Procedimento per la preservazione di materiali cellulosici stampati.
MX20396A (es) Oxazolidinonas fungicidas y procedimiento para su obtencion.
MX14310A (es) Procedimiento para la preparacion de nuevos agentes antiarritmicos, producto obtenido y preparacion farmaceutica que lo incluye.
MX9201847A (es) Derivados heterociclicos de antiserotoninas, procedimiento para su preparacion y medicamentos que los contienen.
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
ES2162929T3 (es) Procedimiento para la preparacion de 2-(1-azabiciclo(2.2.2)oct-3-il)-2,4,5,6-tetrahidro-1h-benz(de)isoquinolin-1-ona y producto intermediario.
MX22522A (es) Procedimiento para la elaboracion de una composici on que contiene alfa-interferon y producto obten ido mediante el mismo.
MX9202763A (es) Nuevos derivados de 2-(1-piperazinil)-4-fenil-cicloalcanopiridina y composicion farmaceutica que los contiene.
MX9201848A (es) Antiserotoninas, procedimiento para su preparacion y medicamentos que las contienen.
MX22255A (es) Compuestos de piridinil-quinolona y procedimiento para su preparacion.
BR8605065A (pt) Processo e dispositivo para a alimentacao de uma secao de material enrolada,especialmente um laminado de empacotamento
MX17107A (es) Procedimiento para la preparacion de tiazolo-(1,5)-benzodiazepinas y producto obtenido
MX164118B (es) Producto embutido y metodo para embutir el mismo
BR9001639A (pt) Artigo,container e processos para preparacao dos mesmos
MX9203383A (es) Nuevos derivados de piridobenzoindol y composiciones farmaceuticas que los contienen.
BR9002456A (pt) Copolimero,artigo e processo para a preparacao de copolimero
ES2055421T3 (es) Uso de clormetiazol en la fabricacion de un medicamento para la prevencion y/o el tratamiento de neurodegeneracion.